Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REFILE-After 4.2 million COVID-19 cases in November, U.S. pins hope on vaccine

Tue, 01st Dec 2020 15:10

(Deletes extraneous "refuse to" in 2nd paragraph)

WASHINGTON, Dec 1 (Reuters) - The United States entered the
final month of the year hoping that promising vaccine candidates
will soon be approved to halt the rapidly spreading novel
coronavirus after 4.2 million new cases were reported in
November.

The new COVID-19 cases were more than double the previous
monthly record set in October, as large numbers of Americans
still refuse to wear masks and continue to gather in holiday
crowds, against the recommendation of experts.

With outgoing President Donald Trump's coronavirus strategy
relying heavily on a vaccine, a Food and Drug Administration
panel of outside advisers will meet on Dec. 10 to discuss
whether to recommend the FDA authorize emergency use of a
vaccine developed by Pfizer Inc.

A second candidate from Moderna Inc could follow a
week later, officials have said, raising hopes that Americans
could start receiving inoculations before the end of the year,
although widespread vaccinations could take months.

Other global pharmaceuticals including AstraZeneca PLC
and Johnson & Johnson also have vaccines in the
works, leading a member of the Trump administration's "Operation
Warp Speed" program to predict the country could be vaccinated
by June.

"One hundred percent of the Americans that want the vaccine
will have the vaccine by (June). We will have over 300 million
doses available to the American public well before then," Paul
Ostrowski, the vaccine program's director of supply, production
and distribution, told MSNBC television on Monday.

In the meantime, leading health officials are pleading with
Americans to follow their recommendations and help arrest a
pandemic that killed more than 36,000 people in November,
pushing hospitalizations to a record high of nearly 93,000 on
Sunday, according to a Reuters tally.

The widespread impact of the pandemic has led
Merriam-Webster to choose "pandemic" as the Word of the Year
after it racked up the most online dictionary lookups of any
word.

"Sometimes a single word defines an era, and it's fitting
that in this exceptional - and exceptionally difficult - year, a
single word came immediately to the fore," the dictionary
publisher said.

With more than 10,000 people dying and 1.1 million
contracting the novel coronavirus in the week ended Sunday,
Trump has remained focused on overturning the results of the
Nov. 3 election won by President-elect Joe Biden, denying Trump
a second term.

Biden has pledged to make combating the coronavirus his top
priority upon taking office on Jan. 20, saying he will rely on
the best scientific evidence.

In the absence of a federal blueprint to curb the spread of
the virus, states are issuing new or revamped restrictions on
businesses and social life.

California's governor said he may renew a stay-at-home order
in the coming days, warning that ICU admissions are on track to
exceed statewide capacity by mid-December unless public health
policies and social behavior change.

"The red flags are flying," Governor Gavin Newsom told
reporters in an online briefing. "If these trends continue,
we're going to have to take much more dramatic, arguably
drastic, action."

(Reporting by Reuters staff; Writing by Daniel Trotta; Editing
by Bernadette Baum)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.